 | Up a level |
2022
Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas 
ORCID: 0000-0003-3864-8315, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus ORCID: 0000-0001-7080-4643, Hallek, Michael ORCID: 0000-0002-7425-4455, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz and Rixecker, Torben Millard
(2022).
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Lancet Haematol., 9 (2).
S. E133 - 10.
OXFORD:
ELSEVIER SCI LTD.
ISSN 2352-3026
Kaddu-Mulindwa, Dominic ORCID: 0000-0001-8832-252X, Godel, Philipp, Kutsch, Nadine, Heger, Jan-Michel ORCID: 0000-0001-9463-8504, Scheid, Christof, Borchmann, Peter, Holtick, Udo, Held, Gerhard, Thurner, Lorenz, Bewarder, Moritz, Rixecker, Torben and Bittenbring, Joerg-Thomas
(2022).
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Clin. Lymphoma Myeloma Leuk., 22 (7).
S. E498 - 9.
DALLAS:
CIG MEDIA GROUP, LP.
ISSN 2152-2669